Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
The Christie NHS Foundation Trust
National Cancer Institute (NCI)
Rapa Therapeutics LLC
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Hoffmann-La Roche
National Cancer Institute (NCI)
Dragonfly Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Dragonfly Therapeutics
Pfizer
National Institutes of Health Clinical Center (CC)
Immunocore Ltd
Stanford University
National Cancer Institute (NCI)
Wake Forest University Health Sciences
AstraZeneca
Biocon Limited
Merck Sharp & Dohme LLC
Genmab
Seagen Inc.
AI Labs Group S.L
Alpha-9 Oncology USA Inc.
Centre Oscar Lambret
Seagen Inc.
Fondazione del Piemonte per l'Oncologia
BioNTech SE
Dana-Farber Cancer Institute
Eastern Cooperative Oncology Group
Novartis
Fred Hutchinson Cancer Center
Mayo Clinic
BioNTech SE
Aminex Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Perspective Therapeutics